NO983410L - FremgangsmÕter for fornyet behandling av pasienter rammet av hepatitt C ved anvendelse av konsensus-interferon - Google Patents

FremgangsmÕter for fornyet behandling av pasienter rammet av hepatitt C ved anvendelse av konsensus-interferon

Info

Publication number
NO983410L
NO983410L NO983410A NO983410A NO983410L NO 983410 L NO983410 L NO 983410L NO 983410 A NO983410 A NO 983410A NO 983410 A NO983410 A NO 983410A NO 983410 L NO983410 L NO 983410L
Authority
NO
Norway
Prior art keywords
hepatitis
procedures
treatment
patients affected
consensus interferon
Prior art date
Application number
NO983410A
Other languages
English (en)
Other versions
NO983410D0 (no
Inventor
Lawrence M Blatt
Michael Klein
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of NO983410D0 publication Critical patent/NO983410D0/no
Publication of NO983410L publication Critical patent/NO983410L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO983410A 1996-02-05 1998-07-23 FremgangsmÕter for fornyet behandling av pasienter rammet av hepatitt C ved anvendelse av konsensus-interferon NO983410L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/595,440 US5980884A (en) 1996-02-05 1996-02-05 Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
PCT/US1997/000340 WO1997027866A1 (en) 1996-02-05 1997-01-13 Methods for retreatment of patients afflicted with hepatitis c using consensus interferon

Publications (2)

Publication Number Publication Date
NO983410D0 NO983410D0 (no) 1998-07-23
NO983410L true NO983410L (no) 1998-10-05

Family

ID=24383236

Family Applications (1)

Application Number Title Priority Date Filing Date
NO983410A NO983410L (no) 1996-02-05 1998-07-23 FremgangsmÕter for fornyet behandling av pasienter rammet av hepatitt C ved anvendelse av konsensus-interferon

Country Status (15)

Country Link
US (1) US5980884A (no)
EP (1) EP0879059A1 (no)
JP (1) JP2000504010A (no)
KR (1) KR19990082084A (no)
CN (1) CN1217660A (no)
AU (1) AU1531897A (no)
BR (1) BR9700829A (no)
CZ (1) CZ231998A3 (no)
EA (1) EA199800674A1 (no)
HU (1) HUP9900929A3 (no)
IL (1) IL125494A0 (no)
NO (1) NO983410L (no)
SK (1) SK101798A3 (no)
WO (1) WO1997027866A1 (no)
ZA (1) ZA97721B (no)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997031649A1 (en) * 1996-02-28 1997-09-04 Ifi Istituto Farmacoterapico Italiano S.P.A. PHARMACEUTICAL COMPOSITIONS COMPRISING NATURAL HUMAN α-INTERFERON
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
KR20030036189A (ko) * 2000-05-26 2003-05-09 이데닉스(케이만)리미티드 플라비바이러스 및 페스티바이러스의 치료방법 및 조성물
US6878364B2 (en) * 2000-12-01 2005-04-12 Cornell Research Foundation, Inc. Animal model for flaviviridae infection
US20050079579A1 (en) * 2001-02-28 2005-04-14 Guangwen Wei Uses of spatial configuration to modulate protein function
CN1245215C (zh) * 2001-02-28 2006-03-15 四川省生物工程研究中心 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
US8551469B2 (en) * 2001-02-28 2013-10-08 Superlab Far East Limited Treatment of tumors and viral diseases with recombinant interferon alpha
US20060035327A1 (en) * 2001-02-28 2006-02-16 Guangwen Wei Recombinant super-compound interferon and uses thereof
PL369129A1 (en) * 2001-09-28 2005-04-18 Intermune, Inc. Method for treating hepatitis c virus infection in treatment failure patients
US20050031585A1 (en) * 2001-09-28 2005-02-10 Hsu Henry H. Method for treating hepatitis c virus infection in treatment failure patients
WO2003026589A2 (en) * 2001-09-28 2003-04-03 Idenix (Cayman) Limited Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
WO2003030923A1 (en) * 2001-10-05 2003-04-17 Intermune, Inc. Method of treating hepatitis virus infection with a multiphasic interferon delivery profile
MXPA04003239A (es) * 2001-10-05 2004-07-08 Intermune Inc Metodo para tratar la fibrosis hepatica y la infeccion de virus de hepatitis c.
AU2002346686A1 (en) * 2001-12-07 2003-06-23 Intermune, Inc. Compositions and method for treating hepatitis virus infection
MXPA04007876A (es) * 2002-02-14 2005-06-20 Pharmasset Ltd Analogos de nucleosido fluorado modificados.
US20040063912A1 (en) * 2002-03-15 2004-04-01 The Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics
US20030199464A1 (en) * 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
CN101172993A (zh) 2002-06-28 2008-05-07 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2′－c－甲基－3′－o－l－缬氨酸酯核糖呋喃基胞苷
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
DE14169110T1 (de) 2002-06-28 2022-05-12 Centre National De La Recherche Scientifique -Cnrs- Modifizierte 2'- und 3'-Nukleosid-Prodrugs zur Behandlung von Flaviridae-Infektionen
AU2003248748A1 (en) 2002-06-28 2004-01-19 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
KR20050088079A (ko) 2002-11-15 2005-09-01 이데닉스 (케이만) 리미티드 2'-분지형 뉴클레오시드 및 플라비비리다에 돌연변이
EP2319853B1 (en) 2002-12-12 2014-03-12 IDENIX Pharmaceuticals, Inc. Process for the production of 2'-branched nucleosides
WO2004078127A2 (en) * 2003-02-28 2004-09-16 Intermune, Inc. Continuous delivery methods for treating hepatitis virus infection
AU2003225670A1 (en) * 2003-02-28 2004-09-28 Intermune, Inc. Interferon drug therapy for the treatment of viral diseases and liver fibrosis
US7429572B2 (en) 2003-05-30 2008-09-30 Pharmasset, Inc. Modified fluorinated nucleoside analogues
US7585647B2 (en) * 2003-08-28 2009-09-08 Guangwen Wei Nucleic acid encoding recombinant interferon
KR20140059302A (ko) * 2003-08-28 2014-05-15 휴이양테크 (유에스에이), 인크. 변경된 공간 구조를 갖는 인터페론의 용도
CN103145715B (zh) 2003-10-14 2016-08-03 F·霍夫曼-罗须公司 作为hcv复制抑制剂的巨环羧酸和酰基磺酰胺
JP2007519422A (ja) 2004-02-02 2007-07-19 アンブレツクス・インコーポレイテツド 修飾されたヒト四螺旋バンドルポリペプチド及びそれらの使用
US7754718B2 (en) 2004-05-05 2010-07-13 Yale University Antiviral helioxanthin analogs
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
WO2006031725A2 (en) 2004-09-14 2006-03-23 Pharmasset, Inc. Preparation of 2'­fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
KR101329878B1 (ko) * 2005-03-09 2013-11-22 광웬 위 재조합 슈퍼 화합물 인터페론의 용도
EP2305697A3 (en) 2005-07-25 2011-07-27 Intermune, Inc. Macrocyclic inhibitors of Hepatitis C virus replication
DE602006019323D1 (de) 2005-10-11 2011-02-10 Intermune Inc Verbindungen und verfahren zur inhibierung der replikation des hepatitis-c-virus
US7781576B2 (en) 2005-12-23 2010-08-24 Idenix Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
TW200946541A (en) * 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
EP2376088B1 (en) 2008-12-23 2017-02-22 Gilead Pharmasset LLC 6-O-Substituted-2-amino-purine nucleoside phosphoramidates
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
EA019295B1 (ru) 2008-12-23 2014-02-28 Джилид Фармассет, Ллс. Соединения пуриновых нуклеозидов и способ их получения
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
CA2764759A1 (en) * 2009-06-09 2010-12-16 Defyrus, Inc. Administration of interferon for prophylaxis against or treatment of pathogenic infection
WO2011014882A1 (en) 2009-07-31 2011-02-03 Medtronic, Inc. CONTINUOUS SUBCUTANEOUS ADMINISTRATION OF INTERFERON-α TO HEPATITIS C INFECTED PATIENTS
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
JP2013527145A (ja) 2010-03-31 2013-06-27 ギリード・ファーマセット・エルエルシー リン含有活性化剤の立体選択的合成
WO2011159930A2 (en) 2010-06-16 2011-12-22 Medtronic, Inc. Damping systems for stabilizing medications in drug delivery devices
AR084044A1 (es) 2010-11-30 2013-04-17 Pharmasset Inc Compuestos 2’-espiro-nucleosidos
WO2013059638A1 (en) 2011-10-21 2013-04-25 Abbvie Inc. Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
CN103826627B (zh) 2011-10-21 2016-02-24 艾伯维公司 包含至少两种直接抗病毒剂和利巴韦林的组合物在制备治疗hcv的药物中的用途
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US8809354B2 (en) 2011-12-31 2014-08-19 Sheikh Riazuddin 3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
TWI718086B (zh) 2013-01-07 2021-02-11 英屬維爾京群島商遠東超級實驗室有限公司 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物
PL3650014T3 (pl) 2013-08-27 2022-01-31 Gilead Pharmasset Llc Preparat złożony dwóch związków przeciwwirusowych
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect

Also Published As

Publication number Publication date
WO1997027866A1 (en) 1997-08-07
CZ231998A3 (cs) 1999-03-17
EP0879059A1 (en) 1998-11-25
BR9700829A (pt) 1998-07-07
JP2000504010A (ja) 2000-04-04
ZA97721B (en) 1997-08-01
US5980884A (en) 1999-11-09
EA199800674A1 (ru) 1999-02-25
AU1531897A (en) 1997-08-22
NO983410D0 (no) 1998-07-23
CN1217660A (zh) 1999-05-26
KR19990082084A (ko) 1999-11-15
SK101798A3 (en) 2000-03-13
HUP9900929A3 (en) 1999-11-29
IL125494A0 (en) 1999-03-12
HUP9900929A2 (hu) 1999-07-28

Similar Documents

Publication Publication Date Title
NO983410L (no) FremgangsmÕter for fornyet behandling av pasienter rammet av hepatitt C ved anvendelse av konsensus-interferon
ITMI931522A1 (it) Composizione farmaceutiche per il trattamento dell'infezione da virus dell'epatite b (hbv)
NO955291D0 (no) System for viral inaktivering av blod
EP0759979A4 (en) ANTISENSE OLIGONUCLEOTIDES INHIBITION OF HEPATITIS C VIRUS
NO975775D0 (no) Fremgangsmåte for fremstilling av forbindelser med antifugal aktivitet
NO172217C (no) Anlegg for behandling av borekaks
AP9801346A0 (en) Xanthone analogs for the treatment of infectious diseases
EP0494231A4 (en) 6-amino-1,2-benzopyrones useful for treatment of viral diseases
NO964006D0 (no) Fremgangsmåte for kontinuerlig koking av vörter
NO986177L (no) FremgangsmÕte for fremstilling av terapeutisk DNA
NO171507C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive nukleotidderivater
AU5157998A (en) Methods and compositions for treatment of hepatitis c infection
AU3530293A (en) Compositions for the treatment of infection and disease caused by hepatitis B virus (HBV)
NO914997D0 (no) Fremgangsmaate ved behandling av sandstensformasjoner
ID21369A (id) Komposisi farmasi untuk penyembuhan penyakit yang disebabkan oleh virus
AU6605196A (en) Method of treating hepatitis delta virus infection
ZA964094B (en) Compositions and methods for the diagnosis of and vaccination against hepatitis c virus (hcv)
GB9425604D0 (en) Peptides effective for diagnsis of hepatitis C infection
DE69522685T2 (de) Behandlung von blut-plasma
AU7716900A (en) Hcv e2 protein binding agents for treatment of hepatitis c virus infection
ZA932271B (en) Compositions for the treatment of infection and disease caused by hepatitis B virus (HBV)
DK17491A (da) Sugeindretning til anvendelse ved tandbehandling
AU2453697A (en) Use of photopheresis in the treatment of chronic infection by hepatitis c virus
DK401589D0 (da) Fremgangsmaade ved behandling af slagtekroppe ellerdele deraf
DE19980730D2 (de) Radioimmunpharmaka zur Therapie der Hepatitis C

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application